Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Good example why retail does not make money. Wait forever and get shook out right before the light at the end of the tunnel.
Sack check.... Anybody else still fully invested?
Who getting shook out right before a deal could be announced?
good name for him, the situation, or maybe -
The predicament.
Basement cam
indeed - who will it be?
No, people don't
Remember when the dog would chase your car and you slam on the brakes?
Thats the kinda fun these aholes are into!
This stock should be shooting up...... Ridiculous.
putting something up my a** for 40 days might slightly skew my perspective.
Would love to be a fly on the wall
Tooo funny
Great info, thanks.
Please keep us posted.
Bravo!
The hare lost the race. You know the story.
and loooooooooooooooooons!
Anecdotes? LOL! That is real life improvement staring you in the face.
I will take that over any statistical measure anytime.
Called real world buddy, try living in it.
rrroooogggeeerrr....ppplllaaatttooo
Yea man, I wish it was possible to learn something from the trial process.
Hell, my turd softener co. had over a billion cap in phase 3 and never showed any better efficacy than SOC currently on the market. Their only other drug in the pipeline (no pun intended) is another colon greaser in phase 2. Hard to believe our cap, this will explode soon with decent results.
Trading halt?
Looking forward to that monday AM pinch
No better way to kick off a big CTIX week
This article is about another company, but it speaks to the credibility of Adam fuerstein and his parent co. The street.com
Post # of 169941
Adam Feuerstein To Cellceutix (CTIX) Stock, ”Thank You Sir, May I have Another…”
InvestingBiotechBreaking NewsJan 24, 2017
More sham journalism from Mr. Feuerstein.
Time after time, I get persuaded to check out yet another one of Adam Feuersteins pseudo intellectual posts that take issue with any small biotech company working to develop innovative and cutting edge science. While I have often asked him to opine on the perennial penny stock, TST, his parent company, he seems to deflect from that issue and would rather argue that while the provider of his paycheck does not hold much investor credibility, his own work should be credited for providing unbiased, fact filled research, free from selective reason. (Hopefully, you had someone around to provide you with a Heimlich maneuver.)
Adam Takes On CTIX
On Monday, Adam Feuerstein decided that it was time to pick on Cellceutix, a stock trading at slightly over a buck a share. Within his publication, Adam could not have made even the most intentionally misinformed investor more proud.
Despite the fact that CTIX has published several clinical updates that provide compelling data as to why Purisol, their lead candidate to treat psoriasis, is on track to potentially replace the current standard of care, Adam would rather act as though he doesn't have the skill set to open a data link, one that would fill his bully brain with enough information to stop him from writing nonsense.
Well, perhaps it would stop him from writing at least some of the googly-goo, but not all. I feel almost certain that he would still find enough selective material, you know, those items from a safety and tolerability trial, for instance, to persuade his audience that a product failed its primary endpoint.
Gee, even as a political science major turned bully bound pseudo biotech analyst, he should know better than to mix a safety trial with one that is truly working to accentuate efficacy. And, I do know that he does know the difference. But, then his material would not have the same shock value, the kind that is working overtime to prop up The Street (TST) share price, currently balancing unconvincingly at .84 cents, a few pennies higher than its 52 week low of .82 cents. And, if Adam did pay attention to the real data, there would be far less intentional misinformation spewed about CTIX.
Let Innovators Innovate
What bothers me the most about how Adam covers stocks is that he fails to recognize that during the journey to deliver cutting edge and innovative medicine, there will be pitfalls along the way. Large pharma is not immune from the pitfalls, either. It's just that unless Uncle Jim wants his publication to pump a stock, the mood of the research is generally negative, so much so , in fact, that even when the TST biotech mailbag is proven wrong, they will hold on to their arguments tighter than a fat man in spandex.
A great article titled , Adam Who?, is a must read for all. Like the guy or not, it is spot on funny and plum full of facts.
For several years, I read opinion by Adam on Sarepta, probably his biggest pump of all. It was unreal how positive he was on a stock that was full of all the things he despises in other companies, like CTIX.
While he tears into companies that have Sarepta like data, he gave them a pass, as well as pages of free embellished publicity. Sarepta is addressing a small market, the potential revenue is greatly exaggerated, the study failed to demonstrate any truly miraculous results, and the efficacy data is inconsistent. But, he loves them!
With that said, though, I HOPE THAT THE SAREPTA DRUG MAKES IT TO MARKET. In fact, I believe that the FDA is by far the greatest obstacle to patient survival in the world. But, that story is for another day.
CTIX Provides A Technology Lesson
While CTIX was quick to respond to Adam's brutal, but flawed attack, I wonder if he will actually take the time to open the links that management sent him and study. Perhaps he can weed out the preliminary safety data and concentrate on the entire picture.
It's important for readers to know that patients responded extremely well to Purisol treatments. Because the drug is administered orally, patient compliance is significantly greater than current standard of care. Also, positive response rates were equal to or better than current standard of care. And, I would be remiss if I did not add that the drug will likely receive expedited approval through the FDA's 505(b)2 approval process.
Readers owe it to themselves to read the entire response that CTIX provided Adam . It was one ass whoopin' that rightly deserves another, and I am sure it is forthcoming.
Don't get me wrong, though. Sometimes the guy actually makes a good call, and as long as he draws the chart to the exact time parameters, he can make it appear as though he is always right.
But, smoke and mirrors won't cure cancer or any of the other disease and illnesses being addressed by many small and underfunded biotech companies. It's for that reason that the guy should simply drop a pair and properly cover stocks that have promise, despite some temporary weakness in their bank accounts. He should be allowed to keep his warped sense of humor, but, at least he should be expected to give these innovators some breathing room.
Until Adam wants to formally acknowledge himself as a cynical, comedic writer, he should leave the investment jokes to others, and allow small and emerging companies, like CTIX, the chance to prove themselves, without the unnecessary share pounding caused by a misinformed following.
It's simple really. CTIX has some of the best up and coming drugs out there and Leo and Dr. B are holding out for good deals. Af is simply paid (maybe not directly) to improve BP's bargaining position.
Looks like it was 5 mill. Here is a little background on 506(b) offerings.
http://www.crowdcheck.com/lexiconterm/rule-506b
check the last offering, 5 or 6 mill if I remember correctly. Don't recall details but it should be among recent filings about a month ago.
Also, you have insiders buying the offerings, does not get any better than that.
Don't believe they need to improve on either front. Ubiquity will trump efficiency and don't believe WiFi, 5G, ciggs, alcohol, some pharmaceutical drugs, GMO foods, some city water etc. are completely safe - but that's not stopping them.
Would be great if they did improve.
Thanks for the link, 2013 still seems like old news to me, and the regulatory filings for Apple compliance testing by the co were in 2014. Funny how they start the article with "Recent filings" and reporting them 3 years later?
The Street? Lol - they never do fake news to manipulate a stock! Are they the ones, by chance, referencing a 2011 Apple patent?
May go down to the 200 MA @ around 14 and a quarter but I doubt it. Bottom in for me - heading back up.
Wow, that's devastating, all the way down to perform! LOl.
Never mind. Short and distort attack based on 6 year old news. Got a buy from a paid guy, and I did.
Anybody got a heads up on this move. Can't find any news. Technical?
Watt up?
Agree, he should not legitimize this clowns claims by responding.
Just a thought, wonder if Biogen said MS so as not to attract other BP's. My guess is if they like what they see, they will make an offer we can't refuse for the whole store - and soon or never!
They just took their last demented, depraved stab at our co. - trying to help humanity and make a buck.
Boo sky's ahead!
I stand erected... err ah, corrected sir!
Has anyone noticed CTIX has gone green since I started posting today?
your welcome!